CG-0255 (PO)

CG-0255 (口服制剂)

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameCG-0255 (PO)
Drug Alias NameCG-0255 (PO)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsIron deficiencyArterial thrombosisIschemic Stroke +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai CureGene Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai CureGene Pharmaceutical Co LtdShanghai Kejin Consulting Management Co Ltd
Inactive CompaniesN/A
Active IndicationsArterial thrombosisIschemic StrokeThromboembolism +[5] 
Inactive IndicationsIron deficiency

Other Information

ATC CodeN/A
Related LinksN/A